Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of GSK5460025 monotherapy in dMMR/MSI-H solid tumors
NL-OMON61049Phase 2Recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of GSK5460025 in Nonhematologic neoplasms, colorectal cancer (CRC) and endometrial cancer (EC) (3 arms), sponsored by GSK. Primary endpoints: Dose-limiting toxicities, Treatment-emergent serious adverse events and adverse events and 4 more. Started Sep 2026; status: recruiting.
02
Drugs
GSK5460025
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON61049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61049.